Browse the evidence

Higher genetically predicted body mass index (BMI) and fat mass index causally increase the risk of aortic valve stenosis, heart failure, deep vein thrombosis, arterial hypertension, peripheral artery disease, coronary artery disease, atrial fibrillation, and pulmonary embolism.

Maintaining a healthy body weight, specifically by reducing fat mass, is a critical step in preventing a wide range of cardiovascular diseases, including heart failure, coronary artery disease, and aortic valve stenosis. Genetic predisposition to higher BMI increases this risk, suggesting that lifestyle interventions aimed at weight loss and fat reduction are essential for cardiovascular health, regardless of current symptoms.

Higher genetically predicted fat mass index is strongly associated with an increased risk of aortic valve stenosis, with the strongest magnitude of association observed among all cardiovascular conditions studied.

Reducing fat mass is particularly important for preventing aortic valve stenosis, as it shows the strongest association among all cardiovascular conditions studied. Focus on fat loss strategies, such as caloric deficit and aerobic exercise, to specifically target fat mass reduction for better heart valve health.

SGLT2 inhibitors reduce major adverse cardiovascular events (MACE) by 11% and heart failure hospitalization by 23% in patients with type 2 diabetes and established cardiovascular disease.

If you have Type 2 Diabetes and heart disease or heart failure, ask your doctor about SGLT2 inhibitors (like empagliflozin or dapagliflozin). These drugs not only help control blood sugar but have been proven to significantly reduce the risk of heart attacks, strokes, and hospitalizations for heart failure, regardless of your current blood sugar levels.

High-fat diet consumption triggers rapid hypothalamic inflammation (via TLR4/JNK/NF-κB pathways) that causes central insulin and leptin resistance, uncoupling energy balance and driving obesity.

Focus on reducing saturated fats (like palmitic acid) in your diet, as they directly trigger brain inflammation that blocks satiety hormones. This isn't just about calories; it's about protecting your brain's ability to regulate hunger and metabolism.

Saturated fatty acids (SFAs) like palmitate cross the blood-brain barrier and accumulate in the hypothalamus, directly causing insulin and leptin resistance via TLR4 and JNK activation.

Limit intake of saturated fats (found in fatty meats, butter, cheese) to prevent them from entering the brain and blocking weight-regulating hormones.

Hypothalamic inflammation disrupts the blood-brain barrier (BBB), allowing peripheral inflammatory signals and immune cells to enter the brain, further exacerbating metabolic deregulation.

Long-term high-fat diets damage the brain's protective barrier, letting inflammation in. Reducing saturated fats may help maintain this barrier.

Age-related gut dysbiosis triggers chronic low-grade inflammation (inflammaging) and innate immune activation, which drives age-related degenerative pathologies and reduces longevity.

Your gut health is not determined by your birth year but by your biological age and lifestyle. Dysbiosis (an imbalance of gut bacteria) triggers inflammation that accelerates aging. To maintain longevity, focus on dietary patterns that support a diverse microbiome and avoid factors like high-glycemic diets or excessive antibiotic use that promote dysbiosis.

Short-chain fatty acids (SCFAs) like butyrate have dual effects on aging: they can promote healthy aging (e.g., via HDAC inhibition) but also contribute to pathology (e.g., neuroinflammation in Parkinson's models) depending on context.

Short-chain fatty acids (SCFAs) from fiber are generally beneficial for metabolic health and aging. However, in specific neurodegenerative conditions, they may contribute to inflammation. Focus on a balanced diet rather than high-dose supplements if you have underlying neurological risks.

Physical activity and sleep duration are highly polygenic traits with significant heritability driven by central nervous system pathways, rather than just metabolic or muscular factors.

Your natural tendency to be active or sedentary has a genetic component, particularly linked to brain function. This doesn't mean you are stuck; it means you might need to work harder or use different strategies to build activity habits than others. Focus on consistency rather than intensity if starting out.

Pioglitazone, GLP-1 receptor agonists (GLP-1RAs), and SGLT-2 inhibitors are pharmacological agents with potential utility in managing NASH, though GLP-1RAs show more consistent evidence for histological improvement.

If lifestyle changes are insufficient, discuss GLP-1 receptor agonists (like liraglutide or semaglutide) with your doctor. These drugs not only help control blood sugar but have shown the ability to resolve NASH in biopsy-proven cases. They are generally well-tolerated when titrated slowly.

Global dietary micronutrient supplies have improved over the last 50 years, but sub-Saharan Africa is the only region where micronutrient density has declined due to a shift toward lower-density staples like rice and maize.

To improve your diet, prioritize foods that are dense in vitamins and minerals (vegetables, fruits, lean meats, legumes) rather than just filling up on empty calories like refined grains or sugars. In regions where staple crops are low in nutrients, diversifying the diet or using fortification is critical.

Rapid postnatal catch-up growth in children born with low birth weight or intrauterine growth restriction significantly increases the risk of adult obesity, insulin resistance, and metabolic syndrome.

For parents of small babies, aim for steady, healthy growth rather than rapid weight gain. Monitor growth charts and consult pediatricians to ensure catch-up growth is gradual, as rapid acceleration in infancy is linked to higher risks of obesity and insulin resistance later in life.

Maternal obesity and high pre-pregnancy BMI increase the risk of offspring being overweight, having higher body fat, and exhibiting insulin resistance in childhood, independent of birth weight.

Maintaining a healthy weight before pregnancy is one of the most effective ways to protect your child's long-term metabolic health. If you are overweight, focus on gradual, sustainable lifestyle changes before conception to reduce the risk of your child developing obesity and insulin resistance.

Epigenetic mechanisms, including DNA methylation, histone modification, and non-coding RNA regulation, play a critical role in the initiation and progression of metabolic diseases such as type 2 diabetes, obesity, and NAFLD.

Your lifestyle choices (diet, exercise, stress) can influence how your genes are expressed through epigenetic mechanisms. This means metabolic health is not fixed by your DNA sequence alone. Understanding these mechanisms opens the door for precision medicine, including biomarkers for early detection and drugs that target epigenetic modifications.

DNA methylation levels in specific genes (e.g., PGC-1α, FTO, TCF7L2) are altered in patients with Type 2 Diabetes and obesity, serving as potential biomarkers for diagnosis and treatment response.

Blood tests measuring DNA methylation patterns (epigenetic biomarkers) may soon help predict who is at risk for diabetes or who will respond to specific drugs like metformin, allowing for more personalized prevention and treatment strategies.

IL-6 acts as a myokine with dual roles: it enhances glucose metabolism and insulin sensitivity during exercise, but chronic overproduction (e.g., in Duchenne muscular dystrophy) contributes to muscle degeneration and inflammation.

IL-6 is a complex myokine. During exercise, it helps your muscles use glucose and fat efficiently. However, in diseases like Duchenne muscular dystrophy, too much IL-6 causes damage. Inhibiting IL-6 in these specific disease contexts can improve muscle health, highlighting that IL-6's effect depends entirely on the physiological context.

Systemic insulin resistance drives hepatic steatosis in NAFLD by increasing adipose lipolysis and hepatic de novo lipogenesis, while specific saturated fatty acids (like palmitate) cause lipotoxicity, ER stress, and hepatocyte apoptosis, which triggers innate and adaptive immune responses leading to NASH and fibrosis.

NAFLD/NASH is driven by insulin resistance and toxic lipid accumulation (lipotoxicity), not just 'fat in the liver.' Managing insulin sensitivity and reducing saturated fat intake may help, but genetic factors and immune system activation also play critical roles in progression to liver damage.

Saturated fatty acids, particularly palmitate, induce hepatocyte apoptosis via ER stress, JNK activation, and death receptor pathways, while monounsaturated fatty acids (MUFAs) like oleate can be cytoprotective by sequestering palmitate into neutral triglycerides.

The type of fat you eat matters for liver health. High intake of saturated fats (like palmitate) can directly damage liver cells, while monounsaturated fats (like oleate) may help protect the liver by storing toxic fats safely as triglycerides.

Hepatic insulin resistance promotes de novo lipogenesis (DNL) via upregulation of SREBP1c and ChREBP, contributing to liver fat accumulation.

Limiting carbohydrate intake, especially simple sugars, can reduce the substrate and signaling for DNL, thereby lowering liver fat production.

Women exhibit lower biological aging and greater longevity than men, evidenced by molecular biomarkers, higher mitochondrial function, and longer telomeres, despite experiencing higher frailty and worse health outcomes at the end of life.

Biological aging is not identical between sexes. Women generally show molecular signs of slower aging (better mitochondrial function, longer telomeres) and live longer, but often suffer more from frailty and chronic disease in old age. Men may maintain physical function longer but face higher risks of early mortality and specific diseases. Personalized health strategies should account for these inherent biological differences rather than applying a one-size-fits-all approach to aging.

Estrogen and other sex hormones play a protective role in mitochondrial function and aging, with women showing higher mitochondrial gene expression and activity compared to men.

Hormones, particularly estrogen, significantly impact how your cells produce energy and age. Women naturally have more active mitochondria, which contributes to their longer lifespan. As estrogen levels drop after menopause, this protective effect diminishes, potentially accelerating certain aspects of aging. Maintaining metabolic health becomes crucial during this transition.

Telomere length is sexually dimorphic, with women having longer telomeres than men from birth, which may contribute to their longer lifespan, although the causal relationship is complex and influenced by genetics and stress.

Women naturally have longer telomeres, a marker of cellular aging, which may help explain their longer lifespan. However, telomeres shorten due to stress, genetics, and lifestyle factors. While you cannot change your sex, managing stress and maintaining a healthy lifestyle can help preserve telomere length.

The Apnea-Hypopnea Index (AHI) is an imperfect metric for Obstructive Sleep Apnea (OSA) severity because it fails to accurately capture the physiological abnormalities (such as hypoxia and arousal intensity) that drive cardiovascular and neurocognitive outcomes.

If you have been diagnosed with OSA based solely on a low Apnea-Hypopnea Index (AHI) but still experience symptoms like daytime sleepiness, high blood pressure, or poor quality of life, your condition may be under-measured. The standard AHI count often misses the physiological damage caused by oxygen drops or brain arousals. Discuss alternative metrics like 'hypoxic burden' with your sleep specialist to see if your treatment needs align with your symptoms rather than just the event count.

Higher biological age, specifically as measured by DNA methylation estimators (GrimAge, Horvath) and Frailty Index, is independently associated with increased all-cause mortality risk, even after adjusting for chronological age and other biological age measures.

Your chronological age is not your health destiny. Biomarkers like DNA methylation (GrimAge) and Frailty Index provide a more accurate picture of your mortality risk. While you cannot change your birth date, these biological ages reflect your body's current state. High biological age signals elevated risk, but it is modifiable. Focus on interventions that improve physiological function and reduce frailty, as these metrics are strong predictors of longevity. Regular health assessments that go beyond simple age tracking can help identify risks early.